Africa: Global Fund, Pepfar Announce Coordinated Effort to Reach 2 Million People With Lenacapavir for Prep to Significantly Reduce Global HIV Infections

The Global Fund, PEPFAR, CIFF, and BMGF are collaborating to provide affordable access to lenacapavir for HIV prevention, aiming to reach at least 2 million people in three years. Gilead Sciences’ lenacapavir is showing promise in preventing new HIV infections and has been licensed for manufacturing in low- and lower-middle-income countries. The goal is to accelerate progress towards ending HIV/AIDS as a public health threat by 2030 through widespread access to this innovative treatment.

Full Article